Systematic Reviews
Copyright ©The Author(s) 2015.
World J Gastroenterol. May 7, 2015; 21(17): 5359-5371
Published online May 7, 2015. doi: 10.3748/wjg.v21.i17.5359
Table 1 Quality assessment of selected case series according to the Chambers criteria
Indication for FMTAuthorYearPublication type (J, CA)12345678Case series quality rating
CDIAas2003J+++++---Poor
Arkkila2010J-+++++--Poor
Aroniadis2013J+-+++---Poor
Bansal2013J-+--?---Poor
Bobo2013CA+-++++--Poor
Borody2013CA-++-?---Poor
Bowden1981J--+++---Poor
Brandt2012J+++++---Poor
Byrne2008CA++--++--Poor
Eisman1958J--------Poor
Elopre2013J----+---Poor
Fischer2013CA--+++--+Poor
Garborg2010J++-++---Poor
Hamilton2012J++++++++Good
Ihunnah2013CA--++----Poor
Jorup-Rönström2012J+++++---Poor
Kassam2010CA-++++++-Satisfactory
Kelly2012J-++++---Poor
Khanna2013CA+++-++--Poor
Louie2013CA+-------Poor
MacConnachie2009J++--+---Poor
Mattila2012J+++++--+Poor
Mellow2010J-++++---Poor
Miller2010J-+--+---Poor
Neelakanta2011J---++---Poor
Newton2013CA------+-Poor
Potakamuri2013CA-++-?---Poor
Rohlke2010J-+-++---Poor
Rubin2013J+++++---Poor
Shiekh Sroujieh2012CA++++++--Poor
Silverman2010J-+--+---Poor
Yoon2010J+++++---Poor
Youngster2013CA++-+++--Poor
IBDAngelberger2012J-+-+++--Poor
Borody2012CA-+++2+2---Poor
Greenberg2013CA-++-1-1--+Poor
Kump2013CA-+-+++--Poor
Kump2013J++++++-+Poor
Kunde2013J++++++-+/-Poor
Vermeire2012CA-+++++--Poor
IBSPinn2013CA--+-+---Poor
PouchitisLandy2013CA+-++++--Poor
ConstipationBorody2001J----++--Poor
Table 2 Methodological quality of included randomised trials
Ref.Random sequence generationAllocation concealmentBlindingIncomplete outcome dataSelective reporting
Vrieze et al[10]Low1Unclear2Low3Low4Low
van Nood et al[18]Low1Unclear2High3LowLow
Table 3 Treatment information on fecal microbiota transplantation, summarised for all studies
IndicationFirst authorYearPre-treatment with bowel lavage? (Y/N)Route of administration1Number of transplantations (n)Amount of fresh stool per treatment (mL/g/tablespoons)Suspension infused(cc or mL)Donor2ae (n)Withdrawal due to ae (n)Ae potentially associated with fmt3 (n)Sae (n)
CDIAas2003NMU130 gNMG and O00024
Arkkila2010YC1-220-30 mLNMG or H? and ONMNM014
Aroniadis2013NMNM1-2NMNMNMNMNM014
Bansal2013NMU and CNMNMNMG or H? and ONMNMNMNM
Bobo2013NMU and Ce1-2NMNMNMNMNMNMNM
Borody2013NMNM1-42NMNMNM0000
Bowden1981NCe and U1NMNMH and O00034
Brandt2012NMC1NM300-700 cc infusedG and H and O0000
Byrne2008NCe1-3300-500 gNMG and H and O4000
Eisman1958NCe4NMNMO0000
Elopre2013NMU1NMNMG0000
Fischer2013YC1-2NMNMO0000
Garborg2010NU or C150-100 gNMG and H and O00054
Hamilton2012YC1-250 gNMG and H and O155000
Ihunnah2013NMNM1-2NMNMNM5NM024 , 86
Jorup-Rönström2012NMCe1-330 cc suspension30 cc suspensionO0000
Kassam2010NCe1-2NMNMNM0000
Kelly2012YC16-8 tablespoonsNMR0000
Khanna2013NMC150 gNMNM0000
Louie2013YU24-34 caps50 gNMRNMNMNMNM
MacConnachie2009NU130 gNMO000NM
Mattila2012YC120-30 mL100 mL suspensionG and H and O000144
Mellow2010NMC1NMNMNM00034
Miller2010NMC1NMNMG and HNM0NMNM
Neelakanta2011NMC1pt 1: 250 g, pt2: NMNMG or HNMNMNMNM
Newton2013NMNMNMNMNMNMNMNMNM34
Potakamuri2013NMNM1-5NMNMNMNMNMNM2 (14, 16)
Rohlke2010YC1NM200-350 mL infusedG and H and ONMNMNMNM
Rubin2013NU125 mLNMO0000
Shiekh Sroujieh2012NMU or C130-50 gNMNM0000
Silverman2010NCe1-250 mLNMG and H47000
CDIVan Nood2013YU1-2> 50 gNMG and H and O15'015816
Yoon2010NMC1NMNMG and H0000
Youngster2013NMU or C1-2NMNMNM0NM0NM
IBDAngelberger2013YU and Ce3NM23.8 g (16.7-25)U, 20 g (6-21.7)CO50290
Greenberg2013NMU or C + Ce> 1NMNMNM3000
Borody2012NMNMNMNMNMNMNMNMNM0
Kump2013NMC2-5NMNMONM0NM0
Kump2013YC1100-150 gNMO101100
Kunde2013NCe51190 g (70-113)NMG and O91122100
Vermeire2012YU3200 gNMNM303100
IBSPinn2013NMNM1-3NMNMNMNMNMNMNM
PouchitisLandy2013NU130 gNMNMNMNMNMNM
ConstipationBorody2001YCe5-14NMNMNMNMNMNMNM
Metabolic syndromeVrieze2012YU1NMNMONMNMNMNM
Table 4 Donor screening for fecal microbiota transplantation
Screening questionnaire1
A questionnaire addressing risk factors for potentially transmissible diseases
Fecal test
Parasites, including Blastocystis hominis and Dientamoeba fragilis
Clostridium difficile, and enteropathogenic bacteria
Serology
Antibodies to HIV, human T-cell lymphotropic virus types 1 and 2, hepatitis A, B, and C, Cytomegalovirus, Epstein-Barr virus
Treponema pallidum, Strongyloides stercoralis, and Entamoeba histolytica
Table 5 Studies on fecal microbiota transplantation in Clostridium difficile-infection, outcome data
First authorYearPatients enrolled (n)Age (mean ± SD or median, range/IQR)Male sex (n)FUPrimary endpointResolution of diarrheaResolution of diarrhea + free from relapse during FU
Aas200318173 ± 953 mo90 d94%\
Arkkila20103769 (24-90)12 mo92%86%
Aroniadis201313270 (38-89)315 mo (1-42)1-7 d84%, 92%350%
Bansal20131270 (31-96)43 mo> 90 d92%\
Bobo201321470.9 ± 11.9101 mo30 d95%\
Borody2013285F:36 ± 18.1 M: 31 ± 161786%
Bowden19811656 (14-85)712 d12 d81%\
Brandt20127765 ± 172117 mo (3-68)90 d91%81%
Byrne20084562 (30-91)1212 mo96%
Eisman1958445-683< 10 d24-48 h100%100%
Elopre20132648, 4815 yr and 6 wk1 d100%100%
Fischer201312746 ± 17730 d7 d75%/, 92%/375%
Garborg20103975 (53-94)183 mo80 d73%, 83%3\
Hamilton201243569 ± 21122 mo1-2 mo86%, 95%3
Ihunnah201366812 mo (3-51)78%, 89%378% after 12 wk
Jorup-Rönström20123275 (27–94)1226 mo (1-68)69%
Kassam201014165.3 (26-87)77 mo24 h100%
Kelly20122659 (19-86)211 mo (2-30)post FMT92%85%
Khanna201313527 (21-48)81-14 d50%
Louie20132596 mo100%100%
MacConnachie200915181.5 (68-95)144 mo (1-6)5-24 wk73%, 80%367%
Mattila201270170 (22-90)2812 mo12 wk94%89%
Mellow201013167 (32-87)75 mo (1-10)30 d92%85%
Miller2010234-5009 mo, 1 mo9 mo, 1 mo100%\
Neelakanta20112527-39112 mo, 5 mo2 wk, post FMT50%50%
Newton201317690 dpost FMT94%76%
Potakamuri20131373.8 ± 18.825 wk- 18 mo> 1 mo92%46%
Rohlke20101949 (29-82)227.2 yr (6-65)6 mo95%, 100%379%
Rubin2013741863 (6-94)262 mo60 d79%58%
Shiekh Sroujieh20126866 (16-93)100 d1-4 d100%100%
Silverman2010772 (30-88)44- 14 mopost FMT100%100%
Van Nood20131611073 ± 1382.5- 5 mo10 wk81%, 94%381%
Yoon20101266 (30-86)33 wk- 8 yr3-5 d100%100%
Youngster2013122 mo8 wk92%\
Table 6 Studies on fecal microbiota transplantation in inflammatory bowel disease, treatment and outcome data
AuthorPublication yearPatients enrolled (n)Diagnose, disease activityAge (mean ± SD or median,range/ IQR)Male sex (n)FU (mo)Medication use during study (n)Timepoint primary endpoint (mo)Clinical improvementClinical remissionCessation of medication during FU (n/total number of patients on the drug)
Angelberger20135Refractory UC27 (22-51)375-asa (3), Immunosuppressive therapy stopped prior to FMT320%0
Borody201262Active UCM: 42.3 ± 11.5 F: 48.45 ± 16.49401-1981NM92%68%
Greenberg201316Refractory CD (2)/UC (14)239 (20-75)94.5-30Steroids (10), antitnf (4), 6MP (1)After FMT63%Steroids: stopped (4/10), decreased dose (3/10). anti-TNF stopped (1/4)
Kump20139Refractory UCNMNM3356%
Kump20136Refractory UC36 (17-52)312333%0%
Kunde2013103Active UC4(7-20)635-asa (7), 6MP (4), steroids (3)0.2570%30%0
Vermeire20124Refractory CD37.5 (29-50)1220%0%